Market Overview

Intercept Pharma 8-K Shows Co. Is 'shifting guidance for an announcement of the Phase 3 REVERSE trial in NASH patients with compensated cirrhosis from YE17 to 1Q18'

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News Guidance FDA

 

Related Articles (ICPT)